Chronic spontaneous urticaria in an 8-year-old girl treated with omalizumab

Ossorio-García, Lidia; Jiménez‐Gallo, David; Albarrán-Planelles, C.; Arjona-Aguilera, Cintia; Linares‐Barrios, Mario

doi:10.1111/ced.12922

Cited by 13 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This, in combination with the small number of real-world studies, highlights the need for larger studies focusing on efficacy of omalizumab in the subgroup of adolescents with CSU. Case reports of efficacy of omalizumab in children less than 12 years of age have been reported [193, 194]. A limitation of omalizumab is the cost that may be unaffordable in many circumstances.…”

Section: Methodsmentioning

confidence: 99%

Management of chronic urticaria in children: a clinical guideline

et al. 2019

View full text Add to dashboard Cite

The aim of this guidance is to provide recommendations to clinicians and other interested parties on chronic urticaria in children. The Italian Society for Pediatrics (SIP), the Italian Society for Allergy and Immunology (SIAIP), the Italian Society for Pediatric dermatology (SIDerP) convened a multidisciplinary panel that prepared clinical guidelines for diagnosis and management of chronic urticaria in childhood. Key questions on epidemiology, natural history, diagnosis, and management were developed. The literature was systematically searched and evaluated, recommendations were rated and algorithms for diagnosis and treatment were developed. The recommendations focus on identification of diseases and comorbidities, strategies to recognize triggering factors, improvement of treatment by individualized care.

show abstract

Section: Methodsmentioning

confidence: 99%

Management of chronic urticaria in children: a clinical guideline

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Skin prick tests (SPTs) were positive for peanut extract (4+) and soy milk (4+). Specific IgE (sIgE, ImmunoCAP ThermoFisher/Phadia) to the crude extract of peanut and the stable 2S-albumin seed storage protein of Ara h 2, which is associated with systemic reactions to peanut [5], was >100 kU/L in both cases. sIgE for the other seed storage proteins of peanut (Ara h 1 and Ara h 3) was also detected (respectively >100 kU/L and 36.30 kU/L), with no relevant sensitization to Bet v 1 or lipid…”

Section: Conflicts Of Interestmentioning

confidence: 99%

“…Omalizumab is a third-line option (after single and quadruple doses of nonsedating antihistamines) for the treatment of CSU in children aged over 12 years [2]. Since only a limited number of publications to date have documented clinical efficacy and safety in children with CSU aged under 12 years, well-controlled studies with a sufficient number of patients are lacking (Table) [3][4][5][6]. The positive effect of omalizumab has also been confirmed in a 6-year-old child with refractory severe solar urticaria [7].…”

mentioning

confidence: 99%

Omalizumab in An 8-Year-Old Boy With Diabetes Mellitus and Refractory Chronic Spontaneous Urticaria

Jeseňák

Ciljakova

Janickova

et al. 2019

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

“…[8][9][10][11][12][13] Real-life experience information on the use of omalizumab among children and adolescents is based primarily on a few of clinical cases described in the literature (Table 3). [14][15][16][17][18][19][20][21][22] Authors have raised concerns about the standard dosage of 300 mg every 4 weeks. Sirufo et al described the case of an 8year-old boy with CSU and allergic asthma: this patient was treated with omalizumab at the recommended dosage for asthma in children (75 mg monthly for 6 months), resulting in remission of urticaria over 1 year after the discontinuation.…”

mentioning

confidence: 99%

Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature

Passanisi

Arasi

Caminiti

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

The recent EAACI/GA2LEN/EDF/WAO guidelines recommend omalizumab (anti–IgE) for the management of patients aged ≥12 years with chronic urticaria unresponsive to high–doses second–generation H1–antihistamines (antiH1). However, there is little published information on the success of omalizumab for such a treatment in children. We reported our experience of six patients with chronic spontaneous urticaria (CSU) treated with omalizumab. Mean age of our case series was 14.7 years (range 11–16 years) with a prevalence of male gender (66.7%). All six patients were treated with at least one 6–months course of omalizumab. The average follow–up period was 13 ± 6 months. Only one patient was no responder to omalizumab therapy. Thus far, two patients have experienced a complete CSU regression over 12 months after the final omalizumab administration. The remaining three patients needed a second course of treatment. Our experience demonstrates that omalizumab is effective and safe as treatment option for CSU unresponsive to antiH1, even in adolescent age.

show abstract

Chronic spontaneous urticaria in an 8-year-old girl treated with omalizumab

Cited by 13 publications

References 6 publications

Management of chronic urticaria in children: a clinical guideline

Management of chronic urticaria in children: a clinical guideline

Omalizumab in An 8-Year-Old Boy With Diabetes Mellitus and Refractory Chronic Spontaneous Urticaria

Omalizumab in children and adolescents with chronic spontaneous urticaria: Case series and review of the literature

Contact Info

Product

Resources

About